Taiwan study monitors MS drug fingolimod for side effects
NCT ID NCT04480853
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 30 adults in Taiwan with relapsing-remitting multiple sclerosis who are starting fingolimod (Gilenya), a daily pill that helps control the disease. Over 12 months, researchers will watch for specific side effects like slow heart rate, vision problems, liver issues, and low white blood cell counts. The goal is to make sure the drug is safe for this population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fingolimod (a daily pill that helps control multiple sclerosis by reducing immune attacks on the nervous system)
What this could lead to
If successful, this study will confirm that fingolimod is safe for Taiwanese MS patients, supporting its continued use as a treatment option.
What could go wrong
This is a small, observational safety study (30 people) with no control group, so it cannot prove effectiveness. Side effects like slow heart rate and liver issues are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGKaohsiung City, 83301, Taiwan
-
Novartis Investigative Site
RECRUITINGTaichung, 407219, Taiwan
-
Novartis Investigative Site
WITHDRAWNTainan, 704302, Taiwan
-
Novartis Investigative Site
RECRUITINGTaipei, 10002, Taiwan
-
Novartis Investigative Site
WITHDRAWNTaipei, 11220, Taiwan
-
Novartis Investigative Site
WITHDRAWNTaoyuan, 33305, Taiwan